Michael T. Yin

Distinct CD8+ T-cell types Associated with COVID-19 Severity in Unvaccinated HLA-A2+ Patients

The paper identifies distinct CD8+ T-cell types associated with mild versus severe COVID-19 in unvaccinated HLA-A2+ patients, showing protective immunity correlates with specific cell subsets.

LP.8.1-directed COVID-19 mRNA vaccines durably boost neutralizing antibodies and mitigate ancestral immune imprinting

This study evaluates the effectiveness of LP.8.1-targeted mRNA vaccines in boosting neutralizing antibodies and reducing immune imprinting from ancestral SARS-CoV-2 strains.

ACE-2-like Enzymatic Activity in Anti-SARS-CoV-2 Spike Protein Monoclonal Antibodies

This study identifies monoclonal antibodies with ACE2-like catalytic activity that may contribute to post-acute sequelae of COVID-19.

Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants

This study compares antibody evasion and receptor binding of SARS-CoV-2 subvariants, finding that LP.8.1.1 has high ACE2 affinity, while NB.1.8.1 and XFG show greater antibody evasion.

Do Existing COVID-19 Vaccines Need to Be Updated in 2025?

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

A First-in-Class Dual Degrader of Bcl-2/Bcl-xL Reverses HIV Latency and Eliminates Ex Vivo Reservoirs

This paper demonstrates that PZ703b, a dual Bcl-2/Bcl-xL degrader, reverses HIV latency and reduces the replication-competent reservoir in ex vivo CD4+ T cells from ART-suppressed patients.